UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/528,673	03/23/2005	Tatsuo Hoshino	K21409USWO C038435/018565	2412	
Stephen M Hara	7590 08/27/200 acz	EXAMINER			
Bryan Cave		RAGHU, GANAPATHIRAM			
1290 Avenue of New York, NY		ART UNIT	PAPER NUMBER		
,			1652		
			MAIL DATE	DELIVERY MODE	
			08/27/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/528,673	HOSHINO ET AL.		
Examiner	Art Unit		
GANAPATHIRAMA RAGHU	1652		

	GANAPATHIRAMA RAGHU	1652	
The MAILING DATE of this communication appe	ars on the cover sheet with the d	correspondence add	ress
THE REPLY FILED 04 August 2008 FAILS TO PLACE THIS AF	PPLICATION IN CONDITION FOR	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperfor Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of A replies: (1) an amendment, affidavited al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)	dvisory Action, or (2) the date set forth in ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extraction and the period of extraction and the second of	on which the petition under 37 CFR 1.1: ension and the corresponding amount of hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
 The Notice of Appeal was filed on <u>04 August 2008</u>. A brie date of filing the Notice of Appeal (37 CFR 41.37(a)), or al Since a Notice of Appeal has been filed, any reply must be 	ny extension thereof (37 CFR 41.37	7(e)), to avoid dismiss	al of the appeal.
AMENDMENTS			
 The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further cor 	nsideration and/or search (see NOT		cause
(b) ☐ They raise the issue of new matter (see NOTE belown (c) ☐ They are not deemed to place the application in better	•	ducing or simplifying th	ne issues for
appeal; and/or (d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s):		mpliant Amendment (l	PTOL-324).
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		imely filed amendmer	nt canceling the
7. For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		l be entered and an e.	xplanation of
Claim(s) allowed: Claim(s) objected to:			
Claim(s) rejected: <u>1,2,6-8,13 and 16</u> . Claim(s) withdrawn from consideration: <u>3,4,9-12,14,15,17</u>	<u>and 18</u> .		
AFFIDAVIT OR OTHER EVIDENCE 8. ☐ The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	ıl and/or appellant fail:	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.
 The request for reconsideration has been considered but <u>See Continuation Sheet.</u> 	does NOT place the application in	condition for allowan	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (13. Other:	PTO/SB/08) Paper No(s)		
/GR/	/Rebecca E. Prouty/ Primary Examiner, Art U	nit 1652	

Continuation of 11. does NOT place the application in condition for allowance because: Continuation of 11. does NOT place the application in condition for allowance because: Rejection of claims 1, 2, 6-8, 13 and 16 for New-matter rejection is maintained. Applicants' arguments are considered, but they are found to be non-persuasive because neither the original claims or the amended claims or the specification as written demonstrates: 1) one step in vitro reaction wherein addition of an isolated polypeptide having the SEQ ID NO: 2 is able to directly catalyze/convert substrates such as L-gulose, L-galactose, L-idose and L-talose to L-ascorbic acid; 2) examiner continues to hold the position that L-ascorbic acid is produced only under in vivo conditions wherein a specific strain of E.coli has been transformed with an expression vector comprising a nucleic acid sequence that encodes the polypeptide of SEQ ID NO: 2 i.e., E.coli cellular context possibly providing other enzymes that enable the conversion of substrates such as L-galactose, L-jalactose, L-idose and L-talose to iintermediates/precursors which are subsequently acted upon by the polypeptide having the SEQ ID NO: 2 to form L-ascorbic acid. Furthermore, the arguments put forth by the applicants that in Example 1, control bacteria i.e., bacteria that are not transformed with the expression vector comprising a nucleic acid sequence that encodes the polypeptide of SEQ ID NO: 2 when provided with the substrates such as L-gulose, L-galactose, L-idose and L-talose do not produce L-ascorbic acid, does not conclusively prove that the polypeptide comprising the amino acid sequence of SEQ ID NO: 2 can directly catalyze/convert substrates such as L-galactose, L-galactose, L-idose and L-talose to L-ascorbic acid as the untransformed microrogaism could simply be missing the one necessary enzyme of a multitstep pathway but comprise all other enzymes. The only way to prove the point in contention is the demonstration of one step in vitro reaction wherein addition of an isolated polypeptide having the SEQ ID NO: 2 is able to directly catalyze/convert substrates such as L-gulose, L-galactose, Lidose and L-talose to L-ascorbic acid.

Previous rejection of claims 1, 2, 6, 7 and 13 under 35 U.S.C. 112, second paragraph is being withdrawn due to amendments to the claims.

Previous rejection of claims 1, 2, 6-8,13 and 16 rejected under 35 U.S.C 112, first paragraph is being withdrawn due to amendments to the claims.

Previous rejection of claims 2, 8, 13 and 16 rejected under 35 U.S.C. 102(b) as being anticipated by Sugisawa et al., (1995) is being withdrawn due to persuasive arguments by the applicants.